Organogenesis Holdings IncORGO
Price$1.40

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $457.5M-5.1% YoYTTM through 30 Jun 2026
Net Income -$84.2M-9,874.2% YoYTTM through 30 Jun 2026
Free Cash Flow $20.8MTTM through 30 Jun 2026

Margins

Current
Gross Margin29.0%
EBITDA Margin-4.4%
Operating Margin-189.8%
Net Margin-18.4%

Returns

0.7%ROE
0.6%ROA

Balance Sheet Health

Debt / Equity0.00x
Current Ratio3.52x
Net Debt-$91.4Mnet cash position
Cash & Equivalents$46.1M

Quality Metrics

Altman Z-Score1.17
Piotroski F-Score3 / 9
FCF Margin4.6%
Earnings-Beat Rate50.0%

Multi-Year Trend

Revenue
'19'20'21'22'23'24'25
FY2025: $564.2M
Diluted EPS-$0.79TTM
'19'20'21'22'23'24'25
FY2025: $0.15

Dividend

No dividend

Capital Allocation

R&D Spend$57M
Capex Intensity2.4%
All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.